DMD Large equally mixed donor pool

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
QUICK SEARCH:   [advanced]


     

Drug Metabolism and Disposition Fast Forward
First published on November 8, 2007; DOI: 10.1124/dmd.107.017871

This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
dmd.107.017871v1
36/2/252    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Author home page(s):
Philip A Krieter
Mark Gohdes
Timothy J Musick
Frederick P Duncanson
William E Bridson
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Krieter, P. A
Right arrow Articles by Bridson, W. E
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Krieter, P. A
Right arrow Articles by Bridson, W. E


Received for publication July 26, 2007.
Revised October 31, 2007.
Accepted for publication November 5, 2007.

Pharmacokinetics, Disposition, and Metabolism of Bicifadine in Humans

Philip A Krieter 1*, Mark Gohdes 2, Timothy J Musick 2, Frederick P Duncanson 1, William E Bridson 3

1 DOV Pharmaceutical, Inc. 2 Covance Laboratories, Inc. 3 Covance Clinical Research Unit, Inc.

* Address correspondence to: E-mail: pkrieter{at}dovpharm.com

Abstract

Bicifadine [DOV 220,075; ±-1-(4-methylphenyl)-3-azabicyclo[3.1.0]hexane HCl)] is a non-narcotic analgesic that has proven to be effective for the treatment of acute pain in clinical studies. The pharmacokinetics, disposition, and metabolism of bicifadine were determined in 8 healthy adult male subjects following a single oral dose of 200 mg [14C]bicifadine in solution. The maximum concentration of total drug equivalents and bicifadine in plasma was at approximately 1 h; the elimination half-life was 2.6 and 1.6 h for radioactivity and bicifadine, respectively. Unchanged bicifadine represented 15% of the area under the concentration time curve for total drug equivalents; the rest was due mainly to the lactam (M12), the acid (M3), and the lactam acid (M9). Total recovery of the dose was 92% with most of the radioactivity recovered in the urine in the first 24 h; fecal excretion accounted for only 3.5% of the dose. Approximately 64% of the dose was metabolized to M9 and its acyl glucuronide; another 23% was recovered as M3 and its acyl glucuronide. Neither bicifadine nor M12 were detected in urine or feces. There were no reported serious or severe adverse events during the study.


Key words: absorption, clinical pharmacokinetics, CYP2D, drug development, drug disposition, excretion, human pharmacokinetics, metabolite identification, oral absorption, pharmacokinetics


This article has been cited by other articles:


Home page
 J. Pharmacol. Exp. Ther.Home page
K. L. Nicholson, R. L. Balster, K. Golembiowska, M. Kowalska, J. P. Tizzano, P. Skolnick, and A. S. Basile
Preclinical Evaluation of the Abuse Potential of the Analgesic Bicifadine
J. Pharmacol. Exp. Ther., July 1, 2009; 330(1): 236 - 248.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2007 by the American Society for Pharmacology and Experimental Therapeutics.